Cancer Research

The cancer fighters: John Glick and a legacy of a half century in oncology

A major figure in the fight against cancer, John Glick reflects on his career after decades of working with the Perelman School of Medicine and as director of Penn’s National Cancer Institute for more than 20 years, treating thousands of patients during his tenure.

From Penn Medicine News

Improving patient experiences in cancer clinical trials

Cancer clinical trials (CCTs) provide patients an opportunity to receive experimental drugs, tests, and/or procedures that can lead to remissions. For some, a CCT may seem like their only option. Yet little is known about the experiences of patient participants who withdraw from CCTs.

From Penn Nursing News

Clarifying T cell ‘exhaustion’

T cells, which are among the most powerful weapons in the immune systems of humans and other vertebrates, remain substantially programmed to stay exhausted even many weeks after exposure to a virus ended.

Hannah Messinger



Media Contact


Experts



In the News


Philadelphia Inquirer

More Black patients are participating in clinical trials for cancer treatment at Penn thanks to this effort

Carmen Guerra and Armenta Washington of the Abramson Cancer Center spoke about their efforts to enroll more Black patients with cancer in clinical trials. “When we conduct research, we want to say that what we learn applies to all people,” said Guerra. “But that might not be the case if we are just studying one population.”

FULL STORY →



CBS News

Cancer Moonshot project launched by President Biden 5 years ago leading to many breakthroughs

Robert Vonderheide of Penn’s Abramson Cancer Center in the Perelman School of Medicine spoke about the Cancer Moonshot project, which has led to major federal funding for cancer research and subsequently, new treatments for patients. “It’s new initiatives, new therapies, and new ways importantly to prevent cancer in the first place,” he said.

FULL STORY →



The Washington Post

For those at risk for cancer, weighing the risk of COVID-19 with delays in screening and treatment

Lawrence Shulman of the Perelman School of Medicine says declining numbers of new cancer diagnoses over the past four months don’t mean fewer people actually have cancer. “There are a lot of patients out there who have cancer but are not undergoing diagnosis and entry into the cancer care system,” he said.

FULL STORY →



New Scientist

CRISPR cancer trial finds that gene-edited immune cells are safe

Edward Stadtmauer and Carl June of the Perelman School of Medicine spoke about a clinical trial that found it safe to inject CRISPR gene-edited immune cells into people with advanced cancer.

FULL STORY →



Science

Deciphering a cancer treatment’s dark side

Saar Gill of the Perelman School of Medicine said it would be easier to treat cancer using CAR-T cell therapy without the looming possibility of triggering cytokine release syndrome.

FULL STORY →



Scientific American

Could immunotherapy treat diseases besides cancer?

Jonathan Epstein of the Perelman School of Medicine is quoted on how immunotherapy has transformed cancer care.

FULL STORY →